Stem Cell-Generated Stomach Organoids to Boost Gastric Disease Research
|
By LabMedica International staff writers Posted on 24 Jan 2017 |

Image: A confocal microscopic image showing tissue-engineered human stomach tissues from the corpus/fundus region, which produces acid and digestive enzymes (Photo courtesy of Cincinnati Children\'s Hospital Medical Center).
Research on gastric diseases will benefit from the development of complex organoid structures containing functional stomach fundic epithelium tissue that were generated from human pluripotent stem cells.
Despite the global prevalence of gastric disease, there are few adequate models in which to study the fundus epithelium of the human stomach. To fill this gap, investigators at Cincinnati Children's Hospital Medical Center differentiated human pluripotent stem cells (hPSCs) into gastric organoids containing fundic epithelium by first identifying and then recapitulating key events in embryonic fundus development.
The investigators reported in the January 4, 2017, online edition of the journal Nature that disruption of Wnt/beta-catenin signaling in mouse embryos led to conversion of fundic to antral epithelium, and that beta-catenin activation in hPSC-derived foregut progenitors promoted the development of human fundic-type gastric organoids (hFGOs). The investigators then used hFGOs to identify temporally distinct roles for multiple signaling pathways in epithelial morphogenesis and differentiation of fundic cell types, including chief cells and functional parietal cells.
"Now that we can grow both antral- and corpus/fundic-type human gastric mini-organs, it is possible to study how these human gastric tissues interact physiologically, respond differently to infection, injury and react to pharmacologic treatments," said senior author Dr. James M. Wells, director of the pluripotent stem cell facility at Cincinnati Children's Hospital Medical Center. "Diseases of the stomach impact millions of people in the United States and gastric cancer is the third leading cause of cancer-related deaths worldwide."
Despite the global prevalence of gastric disease, there are few adequate models in which to study the fundus epithelium of the human stomach. To fill this gap, investigators at Cincinnati Children's Hospital Medical Center differentiated human pluripotent stem cells (hPSCs) into gastric organoids containing fundic epithelium by first identifying and then recapitulating key events in embryonic fundus development.
The investigators reported in the January 4, 2017, online edition of the journal Nature that disruption of Wnt/beta-catenin signaling in mouse embryos led to conversion of fundic to antral epithelium, and that beta-catenin activation in hPSC-derived foregut progenitors promoted the development of human fundic-type gastric organoids (hFGOs). The investigators then used hFGOs to identify temporally distinct roles for multiple signaling pathways in epithelial morphogenesis and differentiation of fundic cell types, including chief cells and functional parietal cells.
"Now that we can grow both antral- and corpus/fundic-type human gastric mini-organs, it is possible to study how these human gastric tissues interact physiologically, respond differently to infection, injury and react to pharmacologic treatments," said senior author Dr. James M. Wells, director of the pluripotent stem cell facility at Cincinnati Children's Hospital Medical Center. "Diseases of the stomach impact millions of people in the United States and gastric cancer is the third leading cause of cancer-related deaths worldwide."
Latest BioResearch News
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read more
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more







